**Recent executive action and procedural acceleration have shaped trader views on marijuana rescheduling timelines.** In December 2025, President Trump issued an executive order directing the Attorney General to complete rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act as quickly as federal law allows. This prompted April 2026 orders from Acting Attorney General Todd Blanche that immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling. The hearing convened June 29, 2026, and concluded no later than July 15, with traders now monitoring subsequent procedural steps such as the August 17 date referenced in coverage for potential further rulings or a final rule. Partial rescheduling already provides some regulatory relief for medical products, while the outcome for adult-use cannabis remains tied to the remaining rulemaking process and any appeals.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$795,647 ปริมาณ
Mar 31, 2026
September 30
14%
December 31
27%
$795,647 ปริมาณ
September 30
$0 ปริมาณ
14%
December 31
$186,077 ปริมาณ
27%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive action and procedural acceleration have shaped trader views on marijuana rescheduling timelines.** In December 2025, President Trump issued an executive order directing the Attorney General to complete rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act as quickly as federal law allows. This prompted April 2026 orders from Acting Attorney General Todd Blanche that immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling. The hearing convened June 29, 2026, and concluded no later than July 15, with traders now monitoring subsequent procedural steps such as the August 17 date referenced in coverage for potential further rulings or a final rule. Partial rescheduling already provides some regulatory relief for medical products, while the outcome for adult-use cannabis remains tied to the remaining rulemaking process and any appeals.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$795,647วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Recent executive action and procedural acceleration have shaped trader views on marijuana rescheduling timelines.** In December 2025, President Trump issued an executive order directing the Attorney General to complete rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act as quickly as federal law allows. This prompted April 2026 orders from Acting Attorney General Todd Blanche that immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling. The hearing convened June 29, 2026, and concluded no later than July 15, with traders now monitoring subsequent procedural steps such as the August 17 date referenced in coverage for potential further rulings or a final rule. Partial rescheduling already provides some regulatory relief for medical products, while the outcome for adult-use cannabis remains tied to the remaining rulemaking process and any appeals.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$795,647วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Recent executive action and procedural acceleration have shaped trader views on marijuana rescheduling timelines.** In December 2025, President Trump issued an executive order directing the Attorney General to complete rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act as quickly as federal law allows. This prompted April 2026 orders from Acting Attorney General Todd Blanche that immediately moved FDA-approved marijuana products and state-licensed medical cannabis to Schedule III while launching an expedited DEA administrative hearing on broader rescheduling. The hearing convened June 29, 2026, and concluded no later than July 15, with traders now monitoring subsequent procedural steps such as the August 17 date referenced in coverage for potential further rulings or a final rule. Partial rescheduling already provides some regulatory relief for medical products, while the outcome for adult-use cannabis remains tied to the remaining rulemaking process and any appeals.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย